Accuray Incorporated (ARAY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 383 | 396 | 430 | 448 | 447 | 459 | 402 | 406 |
| Operating profit | $m | 8 | -26 | ||||||
| Net profit | $m | 4 | -6 | -5 | -9 | -16 | -2 | -49 | -50 |
| EPS reported | $ | -0.02 | -0.40 | ||||||
| Operating cashflow per share | $ | 0.03 | -0.06 | ||||||
| Capex per share | $ | 0.08 | 0.06 | ||||||
| FCF per share | $ | -0.06 | -0.11 | ||||||
| Free cash flow | $m | -6 | -14 | ||||||
| Net debt | $m | 79 | 107 | ||||||
| Book value equity | $m | 81 | 42 | ||||||
| Book value per share | $ | 0.79 | 0.34 | ||||||
| Number of shares | m | 102.77 | 122.64 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.73 | 3.38 | ||||||
| P/S LTM | x | 0.31 | 0.35 | ||||||
| P/FCF LTM | x | -24.86 | -10.15 | ||||||
| EV/EBITDA LTM | x | 12.83 | -18.11 | ||||||
| EV/Sales LTM | x | 0.57 | 0.44 | ||||||
| Earnings Yield LTM | % | -1.13% | -1.50% | ||||||
| FCF Yield | % | -4.02% | -9.86% | ||||||
| Quality | |||||||||
| ROE | % | -1.96% | -99.04% | ||||||
| ROIC | % | -3.69% | -10.09% | ||||||
| Operating margin | % | +1.71% | -6.58% | ||||||
| Gross margin | % | +32.05% | +27.73% | ||||||
| FCF/Sales | % | -1.24% | -3.45% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +2.68% | -9.99% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +1455.4% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.03 | -0.08 | ||||||
| Net Debt/EBITDA | x | 5.88 | -9.99 | ||||||
| EBIT/Net interest | x | 0.61 | -0.75 | ||||||
| Net debt/market cap | % | +96.97% | +4.92% | ||||||
| Net debt/Equity | x | 0.97 | 2.57 | ||||||
| Gross debt/equity | x | 2.17 | 4.41 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free